Lupin Ltd Q2 FY27 Earnings Call: Margins Compress on US Competition, Sees 29-30% EBITDA in 5 Years

Lupin Ltd held its Q2 FY27 earnings call on November 03, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Double-Digit Growth, But Margin Compression Deepens

• Revenue of Rs.7,827 Cr (incl. other income) — up 11% YoY vs Rs.7,048 Cr in Q2 FY 2025-2026, within the guidance shared in the August 2026 interaction; organic growth was double-digit, driven by India and other developed markets.
• EBITDA (ex-forex and other income) of Rs.1,957 Cr at 25.1% margin — down from Rs.2,138 Cr and 31.3% in Q2 FY 2025-2026, impacted by increased competition in key US products.
• Gross margin at 74.2% — vs 73.3% YoY and 74.6% QoQ; CFO Ramesh Swaminathan attributed the contained impact of the Tolvaptan decline to its concentration in the Americas, mix change elsewhere, and forex tailwinds.
• Employee costs +29% YoY at Rs.1,424 Cr (18.3% of sales) — on annual increments and business growth; manufacturing and other expenses +23% YoY at Rs.2,438 Cr (31.3% of sales) on volumes, field-expansion SG&A and settlement-related license fees.
• Other operating income fell 81% to Rs.42 Cr — vs Rs.216 Cr in Q2 FY 2025-2026, primarily due to lower export benefits under the PLI scheme.
• Net cash of Rs.3,349 Cr — vs Rs.4,636 Cr as of 31 March 2026, largely due to closure of the Vishu Pharma acquisition and dividend payout; operating working capital at Rs.7,542 Cr (87 days) vs 90 days in Q1 FY 2026-2027.

LOE Headwinds Bite; Guidance Held Despite H2 Math

• US revenue of $317 Mn in Q2 FY 2026-2027 — down 13.4% QoQ on constant currency, largely due to increased competition and loss of exclusivity on Mirabegron and Tolvaptan, partially offset by seasonal demand and volume growth in select products.
• Tolvaptan held a 50% share as sole generic — over the last couple of months (Q2 FY 2026-2027); CEO Vinita Gupta said potentially a couple of additional competitors could enter (analyst framed entry in Q3 FY 2026-2027), with the bigger impact on pricing rather than share, and revenue/margin contribution expected to come down significantly.
• FY 2026-2027 US guidance maintained at $1.1-1.2 billion — H1 FY 2026-2027 US revenue was $683 Mn; the implied ~$230 Mn/quarter H2 run-rate was probed by analysts against the ~$100 Mn loss management envisages; Vinita Gupta said Q1 and Q2 were both above plan and the company will "see if we get any upsides to it."
• FY28 (FY 2027-2028) US revenue expected at $1 billion+ — a bar management wants to maintain but was non-committal on matching the FY27 level; Apixaban estimates are included, with Tolvaptan and post-September FY 2027-2028 Mirabegron competition as headwinds, and Apixaban, dalbavancin and biosimilars (particularly pegfilgrastim) as offsets.
• US run-rate into FY29 (FY 2028-2029) — Vinita Gupta affirmed it is fair to assume the US business maintains a $1 billion run-rate in FY29, supported by specialty, complex injectables and respiratory products.
• Pipeline cadence — on track to file 15+ products in FY 2026-2027; over the next 3 years expects to launch 60+ US products including ~25 injectable/respiratory products, 5 biosimilars and 2-3 505(b)(2) products; priority is doubling the share of complex products in the US portfolio.

Channel-Led 505(b)(2) Launch Anchors the Next Leg

• Tentative 505(b)(2) approval for apixaban oral suspension received in Q2 FY 2026-2027 — launch expected in Q1 FY 2027-2028, with share building over subsequent months and quarters as traction develops in targeted channels.
• Brand market of $10+ billion — Vinita Gupta said Lupin has targeted certain channels representing a good percentage of that market; the strategy is channel-led rather than B2C, as a B2C approach would have been aspirational only if multiple years had remained before generic entry.
• Additional investments planned in Q3-Q4 FY 2026-2027 — in market access, channel expertise and relationships to build share during the exclusive window before generics come in; management expects to retain some share post-generics, particularly in segments benefiting from a liquid dosage form.
• ~10-month pre-generic window (analyst's framing) — management hopes to maintain, and potentially enhance, FY28 apixaban revenues in FY29 and FY30, viewing the pre-generic period as likely the most valuable and hoping for a revenue tail.
• "Fairly attractive" margins expected — like an exclusive product, though with some commercial-front investment; the Somerset filing site's capacity has been readied with the global operations & supply chain team to meet the upside scenario in FY28.
• Partnership question left open — Vinita Gupta said Lupin has looked at all opportunities and options regarding a potential Apixaban partner and believes it has a "really strong commercial strategy" for the product.

India Outgrows IPM; Europe Emerges as a Growth Engine

• India grew 14.7% YoY in Q2 FY 2026-2027 — core prescription business up 13.8% on 6% volume growth (Q2 value growth 17.4%, H1 19.5%; overall volume growth 8.6% in Q2 and 6.1% in H1 per Nilesh Gupta); H1 prescription growth of 14.4% vs IPM's 14.3%.
• Chronic mix at 66%, up from 65% in FY 2025-2026 — chronic grew 19.5% in H1 FY 2026-2027 vs IPM's 17.2%; Nilesh Gupta said plans add up to ~70% chronic share but pushed back on treating 70% as a ceiling — "theoretically, that chronic share will keep growing."
• Diabetes grew 25%+ YoY in Q2 FY 2026-2027 — a third consecutive quarter of 20%+ growth, led by humicilin market leadership and the semaglutide injection launch (Lupin is the third-largest generic player, though semaglutide volumes are not large); diabetes, cardiology and dermatology outperformed category growth at 1.5x, 1.1x and 1.5x respectively in H1.
• India tracking ~1.1x the market in H1 vs the 1.2-1.3x guidance — very slow respiratory growth (inhaler-led: MDI, DPI, nebulization) and slower cardiac pulled the average down; Nilesh Gupta expects respiratory to pick up in H2 FY 2026-2027 and sees no reason cardiac should not bounce back, targeting 20-30% ahead of the market in FY 2026-2027.
• ~20 India launches planned in FY 2026-2027 — vs 12 in H1 and 15 in all of FY 2025-2026, supported by a prescription salesforce of nearly 11,400 and 80+ planned launches over the coming years; IPM market growth hit a six-quarter high of 14.7% in Q2.
• Other developed markets grew 46% YoY (Rs.1,182 Cr) — contributing 15% of revenues vs 11% in FY 2025-2026; Europe grew 45% YoY (double-digit even excluding Visu Pharma); exclusive licensing partnership with Ten Points Therapeutics signed to commercialize Uversi, a once-daily dual-agent eye drop for presbyopia, in Europe.
• Emerging markets declined 4% — lower Brazil sales offset double-digit growth in South Africa, the Philippines and Mexico; the decline was primarily due to additional competition in DAPA in Latin America and Brazil, which had delivered tremendous upsides over the prior two years.

Biosimilars Seen as the Larger Opportunity; GLP-1 Entry Deferred

• 5 biosimilars being prepared for US launch — first, pegfilgrastim, already launched through partner Valorum; management plans to ramp up these products "over the next few years" and sees a larger opportunity in biosimilars than injectables over the next 3 to 5 years.
• Biosimilar playbook differs from small molecules — Vinita Gupta said price erosion/discounting "really doesn't help much" in biosimilars and incentives to payers drive substitution; the US market now shows active biosimilar adoption versus 5-8 years ago.
• GLP-1 entry not expected "anytime soon" — patent expiries for semaglutide and other newer peptides sit beyond the 5-year time frame; glucagon and liraglutide are expected to remain the material peptide products over the next couple of years.
• Near-term injectable opportunities flagged — Risperdal Consta, recently launched Sugamadex, and Dalbavancin (via both 505(b)(2) and generic routes); niche iron colloid launches expected, with market size and timelines to be followed up by the IR team.
• Respiratory filings on track — Spiriva Respimat exhibit batches complete with filing on track in FY 2026-2027; Breo (Ellipta platform) expected later in FY 2026-2027 but may slip a couple of months into Q1 FY 2027-2028; targeted 7-8 respiratory products on track to be filed within FY 2026-2027 or within a couple of months of fiscal year-end; etanercept US filing expected later in FY 2026-2027 with a first-wave FY29 position.
• R&D at 7.9% of sales in Q2 (Rs.618 Cr) — 7.7% of sales in H1 (Rs.1,226 Cr); FY 2026-2027 guided at ~8%; management is reviewing R&D spend to maximize opportunities without compromising material products and looking to moderate other lines even while investing in Europe specialty, 505(b)(2)s and biosimilars.

FY28 as an Investment Year; 29-30% EBITDA Ambition Over ~5 Years

• FY 2026-2027 margin guidance of 24-25% maintained — but management flagged margins likely to moderate in coming quarters due to intensifying US competition, increased R&D investment, and higher input costs from the challenging Middle East environment; R&D ~8% of sales and ETR ~27-28% guided (H1 ETR actual: 28.5%).
• 29-30% EBITDA margin achievable within the ~5-year span raised in the question — CFO Ramesh Swaminathan cited 505(b)(2) products, biosimilars and global specialty as high-realization drivers, with secular growth over several quarters while FY28 "could potentially be a period of consolidation."
• FY 2027-2028 positioned as the year of investment — building capabilities for a more resilient business; investments in specialty (particularly Europe), biosimilars and 505(b)(2)s are intended to evolve the developed-market business toward a durable portfolio rather than reliance on one-off exclusives; management is "very excited about prospects over the next five years."
• Cost levers are productivity-led, not discretionary cuts — the current expenditure increase is essentially a settlement-related item that would reverse out (responding to Alankar Garude on Tolvaptan decline); IT/AI spends are in an investment phase playing out over the next few quarters, and over the next 3-4 years IT spends should be much lower as a percentage of sales.
• Up to ~Rs.20,000 Cr of deployable capital (period unspecified) — Ramesh Swaminathan said Lupin would keep a leverage threshold of 2x EBITDA, implying about Rs.16,000-17,000 Cr of debt capacity plus Rs.3,000-4,000 Cr of cash; M&A first choice is specialty acquisitions in Europe and America, with India acquisitions equally important but only at appropriate cost, and growth ambitions in the offtake space globally.
• Long-term India target: novel proprietary products at one-third of India revenues within the next 10 years — built through in-house development and in-licensing; first green propellant MDI in India approved in the week prior to the call.
• Quality/compliance on track — responses submitted for Pitampur Unit 2 with remediation on track; management pleased with inspection outcomes across the network in calendar 2026; zero waste-to-landfill certification across 8 manufacturing sites (7 platinum) and ESG assessments completed for 130 suppliers.